S
DYN icon

SignatureFD’s Dyne Therapeutics DYN Stock Holding History

SignatureFD’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.04K Sell
278
-42
-13% -$724 ﹤0.01% 2781
2025
Q4 		$6.26K Buy
320
+42
+15% +$795 ﹤0.01% 2604
2025
Q3 		$3.52K Sell
278
-12
-4% -$137 ﹤0.01% 2784
2025
Q2 		$2.76K Sell
290
-441
-60% -$4.86K ﹤0.01% 2786
2025
Q1 		$7.65K Buy
731
+133
+22% +$1.9K ﹤0.01% 2460
2024
Q4 		$14.1K Sell
598
-99
-14% -$2.93K ﹤0.01% 2231
2024
Q3 		$25K Buy
697
+58
+9% +$2.31K ﹤0.01% 1930
2024
Q2 		$22.6K Buy
639
+41
+7% +$1.19K ﹤0.01% 1901
2024
Q1 		$17K Buy
598
+19
+3% +$430 ﹤0.01% 2079
2023
Q4 		$7.7K Buy
579
+468
+422% +$4.57K ﹤0.01% 2365
2023
Q3 		$995 Sell
111
-103
-48% -$1.11K ﹤0.01% 2938
2023
Q2 		$2.41K Buy
214
+23
+12% +$271 ﹤0.01% 2751
2023
Q1 		$2.2K Hold
191
– – ﹤0.01% 2776
2022
Q4 		$2.21K Hold
191
– – ﹤0.01% 2784
2022
Q3 		$2K Buy
+191
New +$2.19K ﹤0.01% 2760
2022
Q2 		– Sell
-71
Closed -$1K – 3161
2022
Q1 		$1K Buy
+71
New +$604 ﹤0.01% 2971
2021
Q4 		– Sell
-49
Closed -$1K – 3142
2021
Q3 		$1K Buy
+49
New +$869 ﹤0.01% 2809

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

SignatureFD's DYN Position: Q1 2026 in Review

SignatureFD reduced its Dyne Therapeutics (DYN) stake by 13% in Q1 2026, selling an estimated $724 and leaving 278 shares worth $5.04K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

SignatureFD first reported a position in DYN in Q3 2021 and has held it in 17 quarters since. The position peaked at $25K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • SignatureFD held 278 shares of Dyne Therapeutics worth $5.04K as of Q1 2026.
  • SignatureFD sold 42 Dyne Therapeutics shares in Q1 2026, an estimated $724.
  • Dyne Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2781 holding.
  • SignatureFD first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • SignatureFD's Dyne Therapeutics position peaked at $25K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.